Article Figures & Data
Figures
- FIGURE 1.
Schematic of identified PSMA-positive lesion locations.
- FIGURE 2.
Cumulative total scan positivity rate (relative to entire population in treatment groups RP [n = 1,018], RP and PORT [n = 593], or definitive RT [n = 394]). Percentage of individual PSMA-positive disease locations as listed in Figure 1 and cumulative locoregional and distant disease positivity rates are from PSMA scans rated positive (RP, n = 678; PORT, n = 485; RT, n = 376).
Tables
Characteristic RP (n = 1,018 [51.2%]) PORT (n = 593 [29.4%]) RT (n = 394 [19.4%]) Site (n) University of Michigan 372 (36.5%) 264 (44.5%) 192 (48.7%) University of California San Francisco 109 (10.7%) 82 (13.8%) 81 (20.6%) UCLA 537 (52.8%) 247 (41.7%) 121 (30.7%) Age (y) Median 68 (IQR, 63–73) 70 (IQR, 65–74) 72 (IQR, 67–77) No. missing 0 0 0 PSA at scan (ng/mL) Median 0.78 (IQR, 0.4–2.3) 1.58 (IQR, 0.7–3.3) 5.7 (IQR, 3.4–10.9) No. missing 0 0 0 PSA nadir (ng/mL) Median 0.2 (IQR, <0.1–0.3) <0.1 (IQR, <0.1–0.7) 0.3 (IQR, 0.1–0.8) No. missing 458 212 46 Initial PSA at diagnosis (ng/mL) Median 7 (IQR, 5.1–11.3) 6.4 (IQR, 4.7–10.2) 7.6 (IQR, 5.4–7.6) No. missing 651 336 209 T-stage (RP) Median 8 (IQR, 6–10) 7 (IQR, 6–10) NA No. missing 230 433 Clinical T-stage Median 3 (IQR, 3–4) 3 (IQR, 3–4) 3 (IQR, 3–6) No. missing 19 433 126 Gleason grade group (RP) Median 3 (IQR, 2–5) 3 (IQR, 2–5) NA No. missing 19 5 Gleason grade group at biopsy Median 3 (IQR, 2–4) 3 (IQR, 2–4) 3 (IQR, 2–4) No. missing 727 403 5 PSMA injected dose (MBq) Median 200 (IQR, 185--229) 204 (IQR, 185--229) 215 (IQR, 185--233) No. missing 4 3 1 Treatment-to-scan interval (mo) Median 40.2 (IQR, 8.4–104.0) 82.3 (IQR, 48.4–130.6) 75.4 (IQR, 40.3–122.5) No. missing 23 15 24 NA = not applicable.
T-stage nomenclature: T1 = 1, T1a = 2, T1b = 3, T1c = 4, T2 = 5, T2a = 6, T2b = 7, T2c = 8, T3 = 9, T3a = 10, T3b = 11, T4 = 12.
- TABLE 2.
68Ga-PSMA-11 Per-Patient Detection Rate Stratified by PSA Level and Prior Therapy
Total RP PORT RT PSA range (ng/mL) No. Neg. No. Pos. % Pos. No. Neg. No. Pos. % Pos. No. Neg. No. Pos. % Pos. No. Neg. No. Pos. % Pos. <0.25 64 52 44.8 61 44 41.9 3 8 72.7 0.25–<0.5 160 163 50.5 138 120 46.5 22 43 66.2 0.5–<1.0 104 234 69.2 70 136 66.0 34 98 74.2 1.0–<2.0 66 235 78.1 40 128 76.2 26 107 80.5 2.0–<5.0 46 414 90.0 18 120 87.0 19 131 87.3 9 163 94.8 5.0–<10.0 18 238 93.0 10 74 88.1 3 55 94.8 5 109 95.6 ≥10 8 203 96.2 3 56 94.9 1 43 97.7 4 104 96.3 Total 466 1539 76.8 340 678 66.6 108 485 81.8 18 376 95.4 Neg. = negative; Pos. = positive.
All groups combined RP PORT RT Site n TP FP PPV n TP FP PPV n TP FP PPV n TP FP PPV Prostate and prostate bed 77 64 13 0.83 10 8 2 0.80 7 6 1 0.86 60 50 10 0.83 Pelvic lymph nodes 47 34 13 0.72 25 16 9 0.64 19 16 3 0.84 3 2 1 0.67 Soft tissue 43 38 5 0.88 7 5 2 0.71 26 25 1 0.96 10 8 2 0.80 Bone 12 10 2 0.83 2 2 0 1.00 4 3 1 0.75 6 5 1 0.83 Total 179 146 33 0.82 44 31 13 0.80 56 50 6 0.89 79 65 14 0.82
Supplemental Data
Files in this Data Supplement:
